Status:
UNKNOWN
The Effect of Remifentanil on ED95 of Remimazolam for Loss of Consciousness in Adult Patients
Lead Sponsor:
Ajou University School of Medicine
Conditions:
Remimazolam
Eligibility:
All Genders
19-65 years
Phase:
NA
Brief Summary
This study prospectively uses the biased coin technique to investigate the effect of concomitant administration of remifentanil on the 95% effective dose of intravenous remimazolam (Effective dose 95 ...
Eligibility Criteria
Inclusion
- The adult patients who are scheduled to surgery under general anesthesia
Exclusion
- Severe obesity (BMI \> 30 kg/m2)
- Allergy to remimazolam or remifentanil
- Under conditions which make it difficult to respond to the investigator's verbal commends like hearing impairment, etc.
- Patients with general conditions are more than ASA class III
- Patients with brain disease (dementia, cerebral infarction, etc.)
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05434494
Start Date
July 1 2022
End Date
August 31 2023
Last Update
June 28 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.